MicrosensDx

MicrosensDx is a dynamic and ambitious organisation, built from a solid base back in 2001.

With three patent families covering sample preparation, protein aggregation and inflammation/sepsis, MicrosensDx is driven to produce innovative products that enhance patient management and ultimately improve health outcomes.

During the Covid pandemic, MicrosensDx responded rapidly to market demand with a 30 minute, near patient testing platform utilising LAMP technology.  This was supported by our RapiPREP Nucleic Acid extraction reagents.  Prior to this, the companies protein aggregation IP for BSE (Mad Cow Disease) has been licensed to a global veterinary health company where it has enabled thousands of cattle to be tested.

The future focus of the company is around further development of our RapiPREP sample preparation technology and inflammation and sepsis diagnostics.